Salarius Pharmaceuticals Adds Memorial Sloan Kettering Cancer Center and Nationwide Children’s Hospital as Clinical Sites for Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma
Salarius Targeting Key Safety and Efficacy Data Milestones in 2020
HOUSTON, Oct. 8, 2019 — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage
oncology company targeting the epigenetic causes of cancers, announced today that Memorial
Sloan Kettering Cancer Center (MSKCC) in New York City and Nationwide Children’s Hospital
(Nationwide Children’s) in Columbus, OH have been added as clinical trial sites in the ongoing
Phase 1/2 clinical trial of Seclidemstat for the treatment of Ewing sarcoma. The addition of
MSKCC and Nationwide Children’s brings the total number of active clinical trial sites to eight.